Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Mini lung organoids could help test new treatments
Scientists have developed a simple method for automated the manufacturing of lung organoids...
Clogged 'drains' in the brain an early sign of Alzheimer’s
'Drains' in the brain, responsible for clearing toxic waste in the organ, tend to get...
World's oldest known RNA extracted from woolly mammoth
The RNA sequences are understood to be the oldest ever recovered, coming from mammoth tissue...
